Company Filing History:
2 out of 2 
2 out of 3 
1 out of 3 
Years Active: 1992-2006
Title: Inventor Terje Espevik: Innovations in Immunology
Introduction
Terje Espevik is a renowned inventor based in Trondheim, Norway, known for his contributions to immunology and the development of advanced antibody therapies. With a remarkable portfolio of six patents, he has significantly advanced the field, particularly in relation to human toll-like receptors.
Latest Patents
Terje's latest inventions include a groundbreaking antibody that specifically targets the human TLR2 receptor. This antibody is designed to bind solely to CD14 cells in a normal human mononuclear cell population, without inhibiting LPS-induced activation. This innovation has implications for treating bacterial infections mediated via the TLR2 receptor, particularly bacterial sepsis. Additionally, Terje has developed substrates with bound polysaccharides and bacterial nucleic acids. This invention enhances the cytokine-stimulating effects of immune-boosting polysaccharides and nucleic acids when coupled to particulate substrates, paving the way for advanced research tools in immunology.
Career Highlights
Throughout his career, Terje Espevik has collaborated with notable institutions, including Nobipols Forskningsstiftelse and Protan Biopolymer A/S. His work has not only contributed to scientific advancements but has also positioned him as a leading figure in the development of therapeutic antibodies.
Collaborations
Terje's research has been enriched by partnerships with esteemed colleagues, including Marit Otterlei and Gudmund Skjak-Braek. Together, they have contributed to the field's understanding of immune responses and the potential utility of new treatment modalities.
Conclusion
In summary, Terje Espevik stands out as an innovative inventor whose work has made significant strides in immunology. His recent patents highlight his commitment to addressing critical healthcare challenges, particularly in the treatment of infections. As Terje continues to push the boundaries of scientific discovery, his contributions will undoubtedly shape the future of immunotherapy.